Predictive Factors for Response to Rituximab in Waldenström's Macroglobulinemia-Reference-Cited by-同舟云学术

Predictive Factors for Response to Rituximab in Waldenström's Macroglobulinemia

Published:2005-03 Issue:4 Volume:5 Page:270-272
ISSN:1526-9655
Container-title:Clinical Lymphoma
language:en
Short-container-title:Clinical Lymphoma

Author:

Dimopoulos Meletios A.,Anagnostopoulos Athanasios,Zervas Constantinos,Kyrtsonis Marie C.,Zomas Athanasios,Bourantas Constantinos,Anagnostopoulos Nicolaos,Pangalis Gerassimos

Publisher

Elsevier BV

Subject

Cancer Research

Reference11 articles.

1. Waldenstrom's macroglobulinemia: clinical features, complications and management;Dimopoulos;J Clin Oncol,2000

2. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity;Byrd;Ann Oncol,1999

3. Phenotypic and clinical evidence supports rituximab for Waldenstrom's macroglobulinemia;Weber;Blood,1999

4. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle- cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma;Foran;J Clin Oncol,2000

5. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia;Treon;J Immunother,2001

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Waldenstrom Macroglobulinemia;Comprehensive Hematology and Stem Cell Research;2024

2. Frontline Management of Waldenström Macroglobulinemia with Chemoimmunotherapy;Hematology/Oncology Clinics of North America;2023-08

3. Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond;Therapeutic Advances in Hematology;2022-01

4. Current Therapeutic Options in Waldenström Macroglobulinemia;Oncology & Hematology Review (US);2019

5. Waldenström’s Macroglobulinemia;Hematologic Malignancies;2018